Entries |
Document | Title | Date |
20080268022 | MEHTODS FOR TREATING AND PREVENTING AILMENTS CAUSED BY HUMAN PAPILLOMAVIRUS - This application discusses methods and compositions for preventing and treating ailments and/or diseases, such as HPV, with carrageenan. Moreover, methods and systems for administering carrageenan are described herein. In some embodiments, carrageenan (i.e., carrageenan, carrageenan prodrugs, carrageenan metabolites, carrageenan derivatives, and so forth) may be used prophylacticly in order prevent and/or slow a subject from receiving an ailment and/or disease. In other embodiments, carrageenan may be used to treat, suppress, and/or ameliorate an ailment and/or disease after a subject has a condition. While carrageenan may be administered alone, in some cases, the beneficial effects of carrageenan can be synergistically or additively improved by co-administering carrageenan with a polyamide, a polyamide-like compound, and/or surfactant. While the active ingredient(s) may be administered in any form, some preferred forms may include the use of a gel, foam, spray, solution or an intravaginal ring comprising the active ingredient(s). | 10-30-2008 |
20090004246 | INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE DELIVERY OF MACROMOLECULES AND WATER-SOLUBLE DRUGS - An intravaginal drug delivery device comprises a device body comprising a hydrophobic carrier material having at least one channel defining at least one opening to the exterior of said device body, said at least one channel being adapted to receive at least one drug-containing insert; at least one drug-containing insert positioned in said at least one channel, said drug-containing insert capable of releasing a pharmaceutically effective amount of at least one drug suitable for intravaginal administration and containing about 1% to about 70% of at least one water-soluble release enhancer, both the drug and the water-soluble release enhancer dispersed in an insert carrier material; wherein said hydrophobic carrier material and said insert carrier material may be the same or different; and wherein said at least one drug-containing insert is exposed on said exterior of said device body when said intravaginal drug delivery device is in use. | 01-01-2009 |
20090035352 | Drug Delivery Particle - A drug delivery particle including a reservoir region having primarily large pores and a metering region. The particle can be highly spherical. | 02-05-2009 |
20090081278 | Drug Delivery System - The subject invention provides a drug delivery system comprising at least one compartment comprising (i) a drug-loaded thermoplastic polymer core layer, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said core layer is loaded with crystals of a first (pharmaceutically) active compound and said intermediate layer is loaded with, crystals of the second (pharmaceutically) active compound. | 03-26-2009 |
20090098188 | Method for delivery of medication using a dissolvable device - A method utilizing a dissolvable device for the internal delivery of medication and more particularly to the use of films made of a safe polymer material incorporating a medication that is released by dissolution of the film over time, and more particularly a treatment method for controlling or regulating the pH in the vagina by stabilizing and adjusting the pH in the vagina by minimizing the impact of the vaginal flora. | 04-16-2009 |
20090220574 | SURAMIN AND DERIVATIVES THEREOF AS TOPICAL MICROBICIDE AND CONTRACEPTIVE - The present invention is directed to methods of inhibiting STDs by topically administering suramin or a derivative thereof to actual or potential sites of infection, and methods of preventing pregnancy by topically applying suramin or a derivative thereof intravaginally. Suramin compositions that include an antimicrobial agent and/or a sperm-function inhibitor are also provided and may advantageously be used in the methods of the invention. A method of simultaneously inhibiting STDs and preventing pregnancy is also provided. Devices impregnated or coated with the topical suramin compositions are further disclosed and may be used to apply the compositions described herein. | 09-03-2009 |
20090274746 | METHODS AND COMPOSITIONS FOR CONTROLLED DELIVERY OF PHYTOCHEMICAL AGENTS - The presently-disclosed subject matter provides compositions and methods for treating a cancer by providing a composition comprising a biocompatible polymeric matrix incorporating an effective amount of a phytochemical agent, a combination of phytochemical agents, or a phytochemical agent and a chemotherapeutic agent. Further, provided is a device for uterine cervical insertion for local delivery. | 11-05-2009 |
20090291117 | FEMALE BARRIER TO PREVENT INFECTIONS FROM HUMAN IMMUNODEFICIENCY VIRUS - The Human Immunodeficiency Virus posses a significant threat to the world's population. Current strategies utilized to treat infectious agents have not been adequate to eradicate such deadly viral infections. HIV seeks out its host, a T-Helper cell, by having utilizing glycoprotein 120 probes to engage CD4 cell-surface receptors located on the surface of a T-Helper cell. Development of protective barrier techniques for women to utilize during sex that incorporate filter mediums that offer HIV virions' probes the opportunity to engage the cell-surface receptors they are seeking offers a means of neutralizing the infectious threat of HIV. Providing barriers with filter mediums comprised of sheets, strips, or spheres of lipid bilayer or virus-like structures or hypoallergenic surfaces to carry cell-surface receptors, each type of medium having affixed cell-surface receptors intended to engage HIV virions provides an effective strategy to prevent AIDS in women. | 11-26-2009 |
20090291118 | UNIVERSAL BARRIER TO PREVENT INFECTIONS FROM HUMAN IMMUNODEFICIENCY VIRUS - The Human Immunodeficiency Virus poses a significant threat to the world's population. Current strategies to treat infectious agents have not been adequate to eradicate such deadly viral infections. HIV seeks out its host, a T-Helper cell, by utilizing glycoprotein 120 probes to engage a CD4 cell-surface receptor located on the surface of a T-Helper cell. Developing devices to offer HIV virions' probes the opportunity to engage the cell-surface receptors they are seeking offers a means of neutralizing the infectious threat of HIV. A device in the form of a solution containing a filter medium comprised of sheets or strips or spheres of lipid bilayer or virus-like structures or hypoallergenic surfaces to carry cell-surface receptors, each type of medium having affixed to its surface cell-surface receptors intended to engage and neutralize the infectious nature of HIV virions provides an effective strategy to avert AIDS. | 11-26-2009 |
20090291119 | POLYMERIC IMPLANT AND A PROCESS FOR OBTAINING A POLYMERIC IMPLANT - The polymeric implant is obtained from a renewable source, comprising a body formed by at least one biodegradable polymer selected from the group consisting of polyhydroxyalcanoates (PHAs) and copolymers thereof, said body incorporating, in its micro-structure, an active ingredient in a sufficient quantity to control at least one oestrus cycle of mammal animals. The invention further refers to a process for obtaining a polymeric implant comprising the steps of: mixing progesterone or progestogen, at least one polymer of the group of PHAs, one polymeric additive defined by poly(ε-caprolactone), and at least one dispersant additive and/or solvent, to obtain a colloidal solution; evaporating the solvent of the colloidal solution, and forming a paste with the components dispersed therein; drying the paste to remove the residual solvents and control the granulometry of the polymer composite; extruding the polymeric composite and moulding the latter in an implant body. | 11-26-2009 |
20090304776 | TRANSMUCOSAL DELIVERY OF THERAPEUTIC AGENTS AND METHODS OF USE THEREOF - Described herein is a transmucosal delivery device and their use for delivering bioactive agents across a mucosal membrane. The delivery devices contain a pharmaceutically acceptable oxidizing and agents that facilitates the delivery of the blood stream across the mucosal membrane. | 12-10-2009 |
20090311305 | Vaginal therapeutic device including copper metal and method of treating the vaginal using the vaginal therapeutic device - A vaginal therapeutic device made of copper metal has a shape to fit in the vagina and utilizes the copper metal as an antimicrobial agent to therapeutically treat abnormal biological conditions in the vagina. | 12-17-2009 |
20100098745 | Methods for delivery of medication using dissolvable devices - A method utilizing a dissolvable device for the internal delivery of medication and more particularly to the use of films, fibers or non-woven fabrics made of a safe polymer material incorporating a medication that is released by dissolution of the films, fibers or non-woven fabrics over time, and more particularly a treatment method for controlling or regulating the pH in the vagina by stabilizing and adjusting the pH in the vagina by minimizing the impact of the vaginal flora. | 04-22-2010 |
20100104619 | DELIVERY SYSTEM FOR A NON-STEROIDAL NON-IONIZED HYDROPHILIC DRUG - This invention relates to an extended release formulation comprising a solid non-steroidal non-ionized hydrophilic drug, having a molecular weight below 500 Dalton and having a solubility of at least 0.1 wt % in ethylene vinyl acetate copolymer having a vinyl acetate content of 28%, which formulation is a vaginal device having a skin and which device comprises an inner compartment made of a thermoplastic polymer, which polymer is containing the drug. The polymer is preferably made of ethylene-vinyl acetate copolymer. | 04-29-2010 |
20100330149 | Solid Drug Tablets for Implantable Drug Delivery Devices - A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is greater than 70 wt % drug, with the balance being excipient. For example, the anesethetic agent may include lidocaine, in a salt or base form, combined with binder and lubricant excipients. Implantable drug delivery devices including the tablets are also provided, e.g., one or more of the drug tablets may be contained in a biocompatible housing. The drug tablets may be substantially cylindrical with flat end faces, and the device may have from 10 to 100 drug tablets aligned in the housing with the flat end faces of adjacent tablets abutting one another. | 12-30-2010 |
20110008409 | PHARMACEUTICAL PREPARATION CONTAINING A GESTAGEN, AND KIT AND METHOD FOR TREATING ENDOMETRIOSIS USING THE PREPARATION - The pharmaceutical preparation for treating endometriosis contains at least 28, preferably 30, daily dose units, each of which contain dienogest, cyproterone acetate, or chlormadinone acetate at a daily dose that is at most twice that required to inhibit ovulation together with one or more pharmaceutical aids and/or carriers. The daily dose units are administered in a method of prophylaxis and/or therapy of endometriosis continuously during a time interval of at least 169 days or 25 weeks, preferably more than two years. The method effectively reduces endometriosis and associated pain, while undesirable side effects including bone density decrease are reduced or eliminated. | 01-13-2011 |
20110027341 | DEVICE FOR IN SITU PRODUCTION AND TOPICAL ADMINISTRATION OF ALLICIN - The present invention relates to a drug delivery device that is useful for topical treatment of various infections such as skin and nail, or vaginal infections. More specifically, the invention provides a device for topical administration of allicin to an infection site, comprising either one solid carrier or two adjacent solid carriers, dry alliin and dry alliinase, wherein either a mixture of said dry alliin and dry alliinase is contained within said one solid carrier or dry alliin and dry alliinase are each separately contained within each one of said two adjacent solid carriers, whereby in contact with the infection site and a wetting agent, the alliinase acts on the alliin and allicin is produced in situ and administered to the infection site | 02-03-2011 |
20110059154 | CCR5 ANTAGONISTS AS PROPHYLACTICS FOR PREVENTING HIV INFECTION AND METHODS OF INHIBITING TRANSMISSION OF SAME - Topical cream, ointment, lotion, gel, foam formulations and slow release formulations or devices are provided including certain CCR5 antagonists as prophylactics for the prevention, retardation or inhibition of transmission of Human Immunodeficiency Virus (HIV) infection from one human to another. | 03-10-2011 |
20110189257 | NANOPARTICLE BASED THERAPY FOR AGGREGATING MUCIN - There are provided compositions and methods to aggregate mucus using a plurality of positively charged nanoparticles. There are also provided compositions and methods for inducing contraception in the subject. | 08-04-2011 |
20110274740 | METHODS OF REDUCING SYMPTOMS IN SUBJECTS USING SINGLE DOSAGE FORMS WITH TAPERING RELEASE RATES - The present invention is directed to methods of reducing symptoms associated with an abrupt reduction in an endogenous or exogenous chemical in subjects, the methods comprising: (a) administering to the subject a single dosage form comprising an active agent, wherein the release rate of the active agent from the single dosage form tapers throughout the administration; and (b) removing the single dosage form from the subjects after the release rate of the active agent is at or below a terminal symptom threshold level. | 11-10-2011 |
20110305744 | PREPARATION FOR VAGINAL AND RECTAL USE AND RELATIVE PRODUCTION METHOD - A preparation for vaginal and rectal use comprising hyaluronic acid, with an average particle size comprised between about 50 micrometers and about 200 micrometers and a molecular weight comprised between about 1,000,000 Da and about 1,800,000 Da. | 12-15-2011 |
20120058171 | ZOO-TECHNICAL DRUG DELIVERY DEVICE - The present invention relates to a veterinary zoo-technical drug delivery system (device) for the simultaneous release of two or more active substances, which system releases the active substances in a substantially constant ratio over a prolonged period of time. The drug delivery system can be in different forms, such as e.g. an implant, or a intravaginal device such as a helical coil, a spring or a ring. | 03-08-2012 |
20120093910 | NON-HORMONAL VAGINAL CONTRACEPTIVE - The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device. | 04-19-2012 |
20120148655 | MULTI-LAYERED GRADIENT VAGINAL RING - Multi-layered vaginal rings | 06-14-2012 |
20130115265 | DRUG DELIVERY SYSTEM - The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form. | 05-09-2013 |
20140030311 | MONOLITHIC INTRAVAGINAL RINGS COMPRISING PROGESTERONE AND METHODS OF MAKING AND USES THEREOF - The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid. | 01-30-2014 |
20140314826 | NOVEL POLYMERS WHICH RESIST BACTERIAL ATTACHMENT - The invention provides a method for inhibiting bacterial attachment to a surface, the method comprising forming the surface from a polymer, or applying a polymer to the surface, wherein the polymer is a homopolymer formed from a (meth) acrylate or (meth) acrylamide monomer or a copolymer formed from one or more (meth) acrylate or (meth) acrylamide monomers, wherein the (meth) acrylate or (meth) acrylamide monomers are of formula (I) or (II): | 10-23-2014 |
20140328895 | FILM-FORMING COMPOSITION FOR A PH-DEPENDANT SUSTAINED RELEASE OF THE ACTIVE AGENT - The present invention discloses a liquid precursor composition adapted for application on a on a desired surface, this composition comprising: a. at least one therapeutic agent suitable for the treatment or prevention of a disorder or pathological condition, wherein said disorder or pathological condition excludes oral disorders, b. at least one acidic-pH sensitive polymer, c. at least one hydrophobic polymer, and d. a pharmaceutically acceptable volatile solvent, wherein a weight ratio between the at least one hydrophobic polymer and the at least one acidic-pH sensitive polymer is larger than 1. | 11-06-2014 |
20160067225 | AROMATASE INHIBITOR-RELEASING INTRAVAGINAL DEVICE - Described herein is an intravaginal device that provides biologically active circulating concentrations of an aromatase inhibitor for at least about of 4 days. Three compounds with estradiol inhibitory capability (letrozole, anastrozole and fenbendazole) were tested in vitro using bovine granulosa cell culture. Letrozole was found to be the most efficient and potent inhibitor. Liposome-based and a wax-based formulations were used to assess letrozole diffusion through bovine vaginal mucosa in a diffusion chamber study. Samples were collected over a 24 h period. The wax-based vehicle was selected for further development of a letrozole intravaginal device based on its steady release rate. In an in vivo study in cattle, 3 different intravaginal devices containing 3 g of letrozole were tested: Wax (with 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine, DOPE) +gel coat (n=2), Wax+gel coat (n=4) and Wax (n=4). Blood samples were collected serially from time 0 to 120 h, and daily thereafter to measure circulating concentrations of letrozole by LC/MS/MS. The addition of a letrozole-containing gel coating improved initial absorption and hastened the increase on plasma concentrations of the active ingredient, while the letrozole-containing wax-based vehicle maintained prolonged delivery from the intravaginal device. | 03-10-2016 |
20160113905 | Polymer composition and polymer material - A polymer composition including a polymer having a hydroxyl group and a histidine or a histidine derivative grafted to the polymer having a hydroxyl group. A polymer material is also provided, including a polymer composition which includes a polymer having a hydroxyl group, and a histidine or a histidine derivative grafted to the polymer having a hydroxyl group. | 04-28-2016 |
20160120800 | INTRAVAGINAL DRUG DELIVERY DEVICE COMPRISING A POLYURETHANE COPOLYMER - Intravaginal drug delivery device comprising at least one pharmaceutically active substance, and a polyurethane copolymer, wherein the copolymer has the structure according to formula (I): | 05-05-2016 |